A newly available dataset on pharmaceuticals used in Scottish hospitals enabled an Environmental Risk Assessment that includes hospital consumption of pharmaceuticals, as previous UK rankings have been based on community prescription only. As health and the environment are devolved issues for the Scottish government, it is in any case merited to consider a Scottish ranking separately; regional differentiation is particularly relevant in the spatial context of the Water Framework Directive.
BACKGROUND
Pharmaceutical micro-pollutants in aquatic environments and their environmental effects are receiving increasing attention from government institutions [1] , academic researchers [e.g. 2, 3] and the popular press [4] . Recently, the European Commission placed 3 pharmaceuticals -the analgesic diclofenac and the hormones estrone (E1) and 17ß ethinyl estradiol (EE2) -on a "watch list" to gather monitoring data for the purpose of supporting the determination of appropriate measures to address the risk posed by those substances [1] . Pharmaceutical products are used ubiquitously in hospitals and in the community. Following human consumption, excreted residue enters the sewer either as the original parent compound or metabolite and is only partially removed in wastewater treatment works [5] . The continuous input of sewage effluent into surface waters leads to chronic exposure of aquatic organisms and toxic effects can occur at environmentally relevant concentrations [3, 6] .
As thousands of different pharmaceutically active compounds are on the marketapproximately 3000 are licensed in the UK [7] -screening is useful to gauge which pose the greatest environmental risk and might therefore warrant a more detailed risk assessment or environmental sampling and monitoring. In order to decide on approaches and strategies for the reduction of pharmaceuticals in the environment, an understanding of sources is vital. Advanced wastewater treatment technologies are available to remove some pharmaceutical residue [8] , but can be expensive and energy intensive [9] . In some situations, point source treatment at hospitals could be merited [10] . Data on the range, relative amounts and toxicities of medicines used in hospitals and the community can inform decisions on whether and where advanced treatment is appropriate; these decisions will almost certainly need to be country-or region specific.
Prescription data can be used as a starting point for the identification of nationally relevant drugs, such as in Ayscough's screening exercise for the UK Environment Agency [7] , but many 5 previous studies are limited by their adopted method or available datasets for ranking. The UK National Health Service (NHS) stores data on drugs dispensed in the community separately from data on drugs dispensed in hospitals. Previous studies on environmental risk from pharmaceuticals in the UK [11, 12, 13] were based on community prescription data only, excluding hospital consumption. Webb [14] included hospital consumption but limited his assessment to 60 compounds for which ecotoxicity data were available at the time. A further barrier to complete assessment of pharmaceutical consumption is, as remarked by Ayscough et al. [7] as well as Sebastine and Wakeman [12] , that detailed data for over-the-counter (OTC) sales of drugs are not readily available for the UK.
Studies from elsewhere in the EU report that an estimated 20-25% (by total weight) of all human medicine is used in hospitals [15, 16] , but the contribution from hospitals varies per drug. In Germany, the hospital contribution for total antibacterials does not exceed 25%, with cephalosporins and to a lesser extent penicillins showing a relatively high hospital contribution [17] .
For iodinated contrast media (ICM) it is estimated to be approximately 50% [18] ; hospital consumption of the cytostatics is also relatively high. Weissbrodt et al. [16] note that 70% of cytostatics and 50% of ICM consumed in hospitals are administered to outpatients and therefore likely to be excreted in the community. Drugs dispensed to inpatients may also be excreted after the patients are discharged from hospital.
Several studies have measured the contribution to pharmaceutical load made by hospitals.
Ort et al. measured residues in WWTP and hospital wastewater and found low (<15%) hospital contributions for all drugs apart from trimethoprim and roxithromycin [19] . However, in rural areas with no large population centres, large hospitals with a full range of treatment facilities may be encountered in smaller towns, where they will serve a population much greater than that of the town where the hospital is located [9] . Other studies investigating hospital contributions at specific wastewater treatment plants confirm that in some situations hospitals contribute very significantly to overall pharmaceutical load at WWTP: Escher et al. [20] show this using predictive data, Santos et al. [21] and Verlicchi et al. [22] using measured values. Santos et al. [21] found particularly high hospital contributions to loads for receptor antagonists, antibacterials and analgesics, whereas Verlicchi et al. [22] found high contributions for antibacterials, receptor antagonist and lipid regulators. Ort et al. [23] demonstrated that inadequate sampling regimes for hospital wastewater can pose significant uncertainties for the results; using a predictive approach such as in the present study can help identify such uncertainties, e.g. by enabling checks that expected compounds are captured by the sampling process. Predictive data, on the other hand, do not identify strong fluctuations and instead result in average values. As concentrations in hospital effluents are more likely to show such strong variations than community effluents, in the present study, some drugs are highlighted specifically because of their high hospital contribution, which points towards temporal fluctuations and an uneven spatial distribution with potential 'hotspots' of residue near effluents containing hospital wastewater.
Since Jones et al. [13] carried out their ranking exercise in 2002, a dataset for hospital consumption in Scotland has become available. Combined with a dataset on pharmaceuticals dispensed in the community, this enabled us -for the first time in the UK -to prioritise drugs by environmental risk, based on consumption data inclusive of pharmaceuticals used in hospitals.
Because the hospital consumption data covered Scottish hospitals only, the screening exercise was carried out specifically for Scotland. The research methodology is suitable for application in other national or regional contexts.
METHODOLOGY

Data sources, calculation of total consumption and hospital contribution
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Data on pharmaceutical use in the community were purchased from the Scottish National Health Service's Information Services Division (NHS ISD; data derived from the NHS Prescribing Information System) for the top 250 prescribed drug products by quantity (i.e. number of items dispensed) (NHS prescriptions only) for the period April 2010 -March 2011. Hospital consumption data were obtained for the same period of all medicines dispensed in hospitals in Scotland from the Hospital Medicines Utilisation Data (HMUD) database. X-ray contrast media were not included in the database. As for the community data, the active ingredients of the top 250 products by quantity used in hospitals were selected and summed by compound. In accordance with the 'Guideline on the Environmental Risk Assessment of Pharmaceutical Products for Human Use', published by the European Medicines Agency (EMEA) in 2006 [24] , vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids, vaccines and herbal medicinal products were excluded from analysis.
In addition, emollients and barrier preparations (section 13.2 of the British National Formulary, a joint publication by the Royal Pharmaceutical Society and the British Medical Association) were excluded; these are often prescribed in very large quantities and would have dominated the consumption data. Emollients and barrier preparations mostly consist of paraffin and other fatty substances, but can contain antimicrobials such as chlorhexidine gluconate. It is acknowledged that antimicrobials from community consumption are therefore underestimated by the present study; the exclusion was necessary for budgetary reasons and was thought to be preferable to overrepresentation of this group in the data. It is recommended that antimicrobials should be investigated elsewhere in full, taking also into account their extensive use in OTC products.
The current summation of the mass of active compounds in the top 250 products yielded total mass for 165 different compounds. 51 drugs only occurred in the community data, 41 only in the hospital data. Hospital contributions were calculated as It was assumed that all dispensed pharmaceuticals are consumed. A recent survey by Healthcare
Without Harm [25] indicated that most unwanted pharmaceuticals are disposed of via municipal solid waste, in which case our assumption would result in an overestimation of concentrations in WWTP effluent; however, where pharmaceuticals are disposed via the toilet or sink (or vomited up), the amount of active ingredient that enters the environment can be higher than when they are consumed. Specific data on disposal behaviours in hospitals vs. in the community could not be found.
Ranking of pharmaceuticals by risk to the aquatic environment in Scotland
The approach for risk assessment was developed with reference to the aforementioned EU Technical Guidance Document (EU TGD) on Environmental Risk Assessment Part II [26] and the EMEA guideline [24] , which define the potential environmental risk of a substance as a Risk Quotient The predicted environmental concentration is calculated in the first instance as The EMEA guideline stipulates that if PEC unrefined is below 0.01 µg/l, and no other environmental concerns are apparent, the product is unlikely to represent a risk to the environment [24] . After our initial assessment, 31 compounds with PEC (unrefined)w,i < 0.01 µg/l were omitted from further quantitative analysis. Levonorgestrel and ethinyl estradiol were found to have a PEC < 0.01 µg/l, but as very low PNECs (< 0.0001 µg/l) are known for these compounds, they were therefore taken forward to the initial risk assessment, in accordance with the EMEA guideline [24] . Data on percentage excreted as parent compound were mostly taken from Ashley and Currie [30] .
The body of research into removal of pharmaceuticals was reviewed and presented in several studies, most comprehensively in Verlicchi et al. [5] . Removal efficiencies are not available for all compounds and, where they are, there is considerable variation in the values reported. It should be noted that combined sewers are common in Scotland and that therefore sewage may enter the environment untreated via Combined Sewer Overflows (CSO) during heavy rain.
RESULTS
Hospital contributions
Based on the available data, for 43 drugs the hospital contribution was 100% (note that this indicates that the compound was not present in the top 250 community prescribed products, rather than that it is used exclusively in hospitals (although this may be the case), and vice versa). Of these, Attention is also drawn to 2 antiseptic substances: the surgical scrub povidone-iodine and chlorhexidine gluconate, used amongst other things in mouthwash, as well as dimeticone, used in headlice shampoo. None of these have received much attention in the literature from an environmental risk perspective; these compounds are perhaps not strictly speaking medicines but disinfectant and pesticide compounds. All three are available under a General Sales License and, in addition to the amount prescribed, are therefore sold over the counter. The data suggest that the amount consumed in hospitals alone merits further analysis. It should be noted that the hospital contribution of chlorhexidine gluconate could not be calculated accurately due to the exclusion from the community data (as mentioned in the methodology) and that its total consumption is underestimated.
Ranking by mass
Of the considered compounds, paracetamol is prescribed in the highest amount overall, with over 328 t prescribed in 2010. Three other analgesics, ibuprofen, aspirin and codeine, are also all in the top 10 prescribed compounds. Very high consumption is also reported for lactulose (201 t), a synthetic laxative, and for metformin hydrochloride (67 t), a diabetes medicine. The most consumed antibacterial is amoxicillin (13 t), followed by flucloxacillin (6 t).
Overall risk assessment
For the 131 with PEC unrefined > 0.01 µg/l as well as ethinyl estradiol and levonorgestrel all data are given in the Supplementary Information (S.I. course present an uncertainty in the ranking and lack of data is indicated in Table 1 and the S.I.
Similarly, for 1 compound no excretion rate was found and excretion was assumed to be 100%. In the range 0.1 < RQ < 1, a wider range of therapeutic groups feature; the highest ranking drug other than antibacterials is the beta-blocker propranolol at 0.85, which is toxic at very low concentrations. The antifungal clotrimazole has an RQ of 0.84 but, as it is also available over the counter, consumption may be higher. However, as this compound is often used in a cream, it is also possible that unfinished tubes are disposed of with solid waste and do not enter the wastewater.
Again, further research is recommended. Other featured compounds are the painkiller naproxen, the diabetes medicine metformin, the contraceptive hormone ethinyl estradiol, the anti-gout medication allopurinol, 2 antidepressants, an anti-thrombotic drug, 2 more antibacterials, an anticonvulsant, a cholesterol absorption inhibitor, an antacid and a calcium channel blocker.
A number of drugs with a calculated 0.001 < RQ < 0. the available data). Depending on the therapeutic group, these may be used in specific hospital types only; for example, amisulpride and clozapine arise mostly from the 22 mental hospitals in Scotland and will be concentrated around these localities. This could result in locally much higher risks than suggested by the overall RQ; it is suggested that for hospital drugs a different type of risk indicator may be required. This should be the subject of further research.
DISCUSSION
Comparison with measured values
To validate predictions, we were able to compare the results of the UK Water Industries Only the 50 th percentile value for oxytetracycline is 12 times lower than the predicted value.
Overestimation may be due to the assumption that all pharmaceuticals are consumed.
Underestimation may be due to the fact that predictions were based on the assumption of removal in activated sludge, whereas at some facilities less efficient processes such as trickling filters are used for secondary treatment.
Comparison with previous studies
Where possible, results for RQ are compared with those presented in Jones et al. [13] , who ranked the top 25 pharmaceuticals (by mass) in England by environmental risk, and Webb [14] , also noting the compounds with 'top 10' PEC/PNEC ratios in Hilton et al.'s prioritisation for monitoring for the Environment Agency [11] . In the latter, numerical values are not given although the authors state that only lofepramine, dextropropoxyphene and procyclidine had an RQ > 1.
Four of the drugs with RQ > 1, piperacillin, flucloxacillin, tazobactam and ciprofloxacin, have a hospital contribution greater than 20%; none of these was identified as of concern by Webb [14] , Jones et al. [13] , or Hilton et al. [11] . Penicillin V and erythromycin were previously listed as having a much lower RQ (below 0.1) by Jones et al. [13] . Amoxicillin was listed by Jones et al. [13] with an RQ of 588; this can be explained by the fact he assumed no metabolism or removal in sewage treatment works. Oxytetracycline had a higher RQ in rankings by Jones et al. [13] and Webb [14] than was found in the present study.
Of the compounds with 0.1 < RQ < 1, propranolol, naproxen, metformin, and fluoxetine, were all previously identified as having an RQ > 0.1 by Webb [14] , in accordance with our findings;
Hilton et al. [11] previously identified propranolol, clotrimazole, and fluoxetine as of concern. Of the antimicrobials, apart from erythromycin, Hilton et al. highlighted trimethoprim and sulfamethoxazole [11] . The latter two are -according to the data at hand -not the ones posing the greatest risk in Scotland in terms of RQ. Comparison of the PNEC values given in Hilton's study with those found for the ranking in the present study reveals that in the last decade, new toxicity data have become available for nearly all, resulting in higher risk quotients. An RQ > 0.1 for carbamazepine (0.07 in the present study) and ferrous sulphate (0.23 in the present study) had previously been identified by Jones et al. [13] . The authors also considered naproxen, allopurinol, and metformin but found RQ values much lower than found in the present study, as with increasing toxicity data the reported PNEC values have decreased by 2 orders of magnitude for most of these compounds. Venlafaxine, povidone-iodine, clopidogrel, clarithromycin, gentamicin, amlodipine and ezetimibe had not been identified by the studies we used for comparison. Of these, povidone-iodine, clarithromycin and gentamycin have very high hospital contributions, which would explain why they were not included by Jones et al. [13] or Hilton et al. [11] (although povidone-iodine may have been deliberately excluded by the authors as a disinfectant).
Comparison with other national studies
Few other national studies were identified that considered both community and hospital consumption. Huschek et al. [33] Denmark, the following substances were identified: those with 0.01 < RQ < 0.1 were prednisolone, citalopram, metoprolol, tramadol and losartan; those with 0.1 < RQ < 1 were atorvastatin, norethisterone, felodipine, metformin, amlodipine, diazepam, and those with RQ > 1 sertraline, diclofenac, ibuprofen, and aspirin. There is a notable lack of antibacterial drugs on this list; this may be because the study only considered the top 40 most sold substances. Furthermore, the study uses 'defined daily doses' (DDD) as defined by WHO for the calculation of the amount sold, which can be problematic in the case of combination drugs, such as co-amoxiclav or co-codamol, for which no DDD are issued. Hospital contributions in Denmark were much lower than those calculated in the present study; only prednisolone has a hospital contribution over 5%. In Finland, 65 compounds were considered, of which amlodipine, atorvastatin, and aspirin have 0.1 < RQ < 1. Metformin, paracetamol, ibuprofen, naproxen, and several sex hormones have RQ > 1. As in Denmark, no antibacterials were identified as having high risk quotients.
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The comparison with these studies suggests that it is important to include a large number of substances for initial consideration, as some very low PNEC values can result in high risk even for compounds lower on a ranking by mass. There are a lot of similarities between the high ranking compounds in Huschek's study and those in the present study; differences appear to be in some cases due to different PNEC data rather than actual different risks. Based on these trends, we may expect the hospital contributions for amoxicillin and for ciprofloxacin to have increased, the RQ for ciprofloxacin and amoxicillin to have reduced slightly, and the RQ for piperacillin and tazobactam to have increased substantially since the data for the present study were collected. Given the ecotoxicological importance of antibacterial drugs, it would be highly interesting to investigate the environmental consequences of the rapidly developing antimicrobial resistance agenda more fully in a further study.
Trends in consumption
Implications for mitigation
Half of the pharmaceuticals with RQ > 1 have high hospital contributions, whilst a number of compounds with lower RQ may be locally concentrated WWTP serving hospitals and pose a local risk. In such situations, point source treatment of hospital effluent could be an effective strategy for the reduction of environmental risk as a large fraction of the pollutant load could be removed by treating a relatively small amount of wastewater. However, some pollutants of key concern, such as erythromycin and propranolol, would not be effectively targeted by point source treatment as they are predominantly used in the community. To enable informed decision making on treatment options, spatially differentiated risk assessment may be required to prioritise locations and select appropriate mitigation. The marked reduction in use in primary care of the four C's indicates that where the necessary drivers are in place, pharmaceutical use can to some extent be influenced by prescribing policy, implying that such policies could be considered as a preventative measure to reduce environmental risk from pharmaceuticals. Other studies [25] indicate that disposal of waste pharmaceuticals via the sewer is still common despite collection facilities at pharmacies, so that awareness raising may be a useful intervention. No single obvious solution presents itself and it may be that a range of stakeholders and policies have a role to play in the reduction of environmental risk.
CONCLUSIONS AND RECOMMENATIONS
Attention is drawn to a number of drugs not previously highlighted as of concern for the UK.
As expected, for some compounds this is likely due to the inclusion of the hospital consumption data; indeed 4 of these compounds -all with an RQ > 1 -have hospital contributions over 20%.
However, several drugs not previously identified as of concern are predominantly used in the community. Three probable explanations are proposed. Firstly, in the past decade much more experimental ecotoxicity data have become available, in particular for antibacterials, which means lower PNEC values have been established. Based on the available datasets, antimicrobials now have the highest RQs. Secondly, compounds may previously have been excluded from research programmes due to the lack of analytical methods or due to other deliberate exclusions. Thirdly, for yet others a marked increase in consumption is thought to have led to an increased risk to the aquatic environment. The changes from previous prioritisations highlight the importance of regular review.
As hospital drug usage and thus release into the environment is likely to have an uneven spatial distribution, risk quotients for hospital drugs may be locally higher than reported here.
Geographical refinement of the risk assessment is recommended and should take account of any hospitals as well as local dilution rates. Although the available data on consumption, toxicity and removal are improving, gaps remain. For the newly highlighted drugs, it is recommended that further study on removal efficiencies as well as environmental studies are carried out. In order to make a complete, holistic risk assessment of the pharmaceuticals we consume, research is further required on the prevalence, fate and effect of active metabolites and the fate and effect of sorbed pharmaceutical residue and metabolites applied to land via sludge. Furthermore, as in previous studies, the datasets acquired were limited by both availability and price and required extensive and laborious manipulation before they could be used. Whilst the present study was able to identify a number of compounds over a range of treatment groups that carry a moderate or high 23 environmental risk for Scotland, it cannot exclude the possibility that others should also be of concern. As awareness of the issue of pharmaceuticals in the environment is growing and more regularly updated research is clearly required, it would be beneficial if data gathering and storage systems by NHS and other agencies were better suited also to the environmental types of analyses required. Interdisciplinary, multi-agency and international collaboration would be required to improve this situation. * Indicates lack of data, precautionary value used; ** From [4] , mean values were used; † Not ingested; † † Author's estimate; u unrefined; E. Ecosar; RQ = PEC/PNEC*Ecr*(1-R); RQs from , Hilton (2003) and 
